BCL2 and leukemia: Although DT2216 is very useful for the treatment of some BCL-xL-dependent T-cell acute lymphoblastic leukemia and T-cell lymphoma, it has a limited effect on other leukemias and most solid tumors unless combined with ABT199 (venetoclax, a selective BCL-2 inhibitor) or chemotherapy2.